Jack Bartoszek
Geriatric Medicine · Mishawaka, INNPI 1093714818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,180 and has fallen 70.9% since, to $634 in 2025. Among geriatric medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $90.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Amgen$1K
- Esperion Therapeutics, Inc.$872
- AstraZeneca$768
- Novo Nordisk$433
- Otsuka America Pharmaceutical, Inc.$394
- plus $3K from 16 others
What the payments were for
- Food & beverage$7,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $1,079 |
| Amgen | 9 | $1,052 |
| Esperion Therapeutics, Inc. | 7 | $872 |
| AstraZeneca | 7 | $768 |
| Novo Nordisk | 4 | $433 |
| Otsuka America Pharmaceutical, Inc. | 5 | $394 |
| AbbVie(2 entities) | 4 | $354 |
| Lilly USA, LLC | 9 | $325 |
| Pfizer | 3 | $277 |
| Neurocrine Biosciences, Inc. | 2 | $248 |
| Sanofi-aventis U.S. LLC | 2 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $201 |
| GSK | 2 | $178 |
| Nestle Healthcare Nutrition Inc. | 2 | $160 |
| Johnson & Johnson | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Bayer | 1 | $125 |
| Boehringer Ingelheim | 1 | $120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $100 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,403 in reported general payments places this provider in the 90th percentile of 70 geriatric medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $25,117 |
| FanaptIloperidone | 31 | $24,497 |
| RexultiBrexpiprazole | 21 | $17,395 |
| OzempicSemaglutide | 14 | $14,376 |
| JardianceEmpagliflozin | 45 | $13,749 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $11,122 |
| FarxigaDapagliflozin Propanediol | 26 | $7,616 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,303 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $6,419 |
| Atorvastatin Calcium | 235 | $3,828 |
| LantusInsulin Glargine,hum.Rec.Anlog | 42 | $3,484 |
| Sertraline Hcl | 162 | $3,350 |
| HumalogInsulin Lispro | 26 | $3,065 |
| Memantine Hcl | 44 | $2,602 |
| Gabapentin | 104 | $2,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $277 | $25,11785 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $120 | $21,05258 claims |
| GSKAnoro Ellipta, Incruse Ellipta | $178 | $17,54139 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $394 | $17,39521 claims |
| Novo NordiskOzempic | $433 | $14,37614 claims |
| AstraZenecaFarxiga | $768 | $7,61626 claims |
| Lilly USA, LLCHumalog, Olanzapine | $325 | $4,73667 claims |
| Sanofi-aventis U.S. LLCLantus | $204 | $3,48442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 70 geriatric medicine providers in Indiana.
Other geriatric medicine in Mishawaka
- Arnold del PilarMishawaka$25K
- Malaz BoustaniIndianapolis$188K
- Gregory SpanglerKokomo$31K
- Jodie HarperIndianapolis$27K
- Karl SashEvansville$26K
- Lauren DandurandMerrillville$11K
- Elton AmosIndianapolis$7K
- Kofi QuistIndianapolis$5K
- Robert LebowIndianapolis$3K
- Rajarajeswari MajetyDyer$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.